INTRODUCTION
Heart transplantation has evolved into the gold standard treatment for patients with end-stage congestive heart failure [1] . As outcomes of heart transplantation have improved, the number of patients waiting for heart transplantation has markedly increased, and the upper limit of the recipient's age has been raised in some centers [2] [3] [4] . However, it has been suggested that advanced age is considered a relative contraindication for heart transplantation due to the high incidence of co-morbidities such as malignancies, hypertension, diabetes mellitus, and reduced life expectancy after heart transplantation [5, 6] . In addition, heart transplantation in elderly patients is still under debate because the shortage of donor hearts has been aggravated. The aim of this study was to evaluate early-and mid-term results of heart transplantation in patients ≥60 years old when compared with those of heart transplantation in patients ＜60 years old.
MATERIALS AND METHODS

1) Patient characteristics
Between March 1994 and December 2011, 81 patients unSang Yoon Yeom, et al derwent heart transplantation in Seoul National University
Hospital. Sixty-four of the patients were male, and 17 were female. The mean age was 49.1±14.0 years; 60 patients were younger than 60 years at the time of heart transplantation (group Y) and 21 patients were 60 years or older (group O).
Dilated cardiomyopathy was the most common indication for heart transplantation (n=42, 51.9%). Preoperative characteristics were similar in the two groups (Table 1) .
2) Surgical techniques and data
Two techniques for heart transplantation were used. In most patients (96.3%), the bicaval Wythenshawe technique (bicaval and single left atrial anastomoses) [7] was used. The conventional Lower and Shumway technique [8] was used in 3 patients (3.7%) who underwent transplantation in the early period. Seventeen patients (21%) had a history of previous cardiac surgery. The mean donor age was 32.2±10.9 years old. The mean cardiopulmonary bypass (CPB) and donor heart ischemic times were 241±77 and 155±49 minutes, respectively. The mean CPB time in group O was significantly longer than that in group Y (p=0.004) ( Table 2 ).
3) Evaluation of mid-term clinical outcomes
The patients underwent regular postoperative follow-up through the outpatient clinic at 3-month or 4-month intervals.
The patients were also contacted by telephone for conHeart Transplantation in Elderly 
4) Immune suppression protocol
The standard maintenance immune suppression protocol for heart transplantation (so-called "triple therapy") was used: (1) a calcineurin inhibitor such as cyclosporine or tacrolimus, (2) an antiproliferative agent such as azathioprine (AZA, Imuran) or mycophenolate mofetil (MMF), and (3) corticosteroids such as prednisone or prednisolone [9] . Cyclosporine, AZA, and prednisolone were used in the early period until June 1999. At that point, the antiproliferative agent was changed from AZA to MMF. In July 2009, the calcineurin inhibitor was changed from cyclosporine to tacrolimus with an addition of interleukin-2. Intravenous methylprednisolone (500 mg) was administered intraoperatively and followed by 3 doses (150 mg every 8 hours) postoperatively. Prednisone was then given at a daily dose of 1 mg/kg (per oral steroid) and tapered over six months to 0.1 mg/kg per day.
The patients underwent endomyocardial biopsy weekly for 4 weeks after transplantation, every 4 weeks until the third month, and then every 3 months until the second year.
Rejection severity was graded from 0 to 4 based on the International Society for Heart and Lung Transplantation (ISHLT) grading system [10] . Grade 1B and 2 were managed by increasing the dose of oral steroids. Intravenous methylprednisolone (1 g/day for 3 days) was given for ≥grade 3A.
5) Statistical analysis
Statistical analysis was performed using the SPSS ver. unit and hospital stays were also similar in the two groups.
RESULTS
1) Early results
2) Overall survival
Among 77 survivors, late mortality (＞30 days) occurred in 25 patients (32.5%). One-year and 5-year survival rates were 84.6% and 67.9% in group Y and 75.9% and 60.7% in group O, respectively. There was no difference in overall survival between the 2 groups (p=0.201) (Fig. 1) . Multivariate analysis revealed that age ≥60 years was not a significant risk factor for overall survival; postoperative renal failure was the only significant risk factor for overall survival (p=0.011) ( Table 4) .
3) Event-free survival
Freedom from infection at 1 and 3 years was 72.5% and 67.8% in group Y and 63.6% and 63.6% in group O, respectively (p=0.586) (Fig. 2) . Freedom from rejection (ISHLT grade ≥1B) at 1 year was 73.9% in group O and 45.9% in group Y, respectively (p=0.026) (Fig. 3) .
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DISCUSSION
The present study demonstrated two main findings. First, there were no significant differences in the early results and mid-term survival between the elderly patients (≥60 years) and young patients (＜60 years) at the time of transplantation. Second, the elderly patients demonstrated a significantly higher freedom from rejection at 1 year.
Advanced age has traditionally been considered a relative contraindication for heart transplantation [5, 6, [11] [12] [13] . According to the 2011 report from the registry of the ISHLT, increasing recipient age remains an independent risk factor that adversely affects survival after heart transplantation [11] .
Because of the critical shortage of donor organs, selection of candidates for transplantation is based on the potential for maximal benefit in terms of functional recovery and length of survival. In addition, advanced age is associated with shorter life expectancy and higher incidence of comorbidities such as hypertension and diabetes. Because of the rapid increase in the number of elderly patients, the number of candidates for transplantation older than 60 years has steadily increased [11, 14] . However, the recipient age limit for heart transplantation is still a matter of debate [2, 15] . Several studies have shown that heart transplantation in elderly patients could be performed successfully with acceptable morbidity and mortality and enhanced long-term survival, when compared with those of younger patients [2] [3] [4] 16] . Recent advancements in postoperative care after heart transplantation, including the infection control protocols and immune suppression regimen, may have enabled that improvement [9] . In the present study, the early mortality rate was low and there were no differences in 1-or 5-year survival rates of groups Y and O.
Previous studies have demonstrated that the incidence of infection was higher in older patient groups [4, 5, 12, 13] . In the present study, however, freedom from infection until postoperative 3 years was similar in the 2 groups. This seems to be due to improvements in the medications for infection control and immune suppression. Previous studies have also demonstrated that the incidence of acute cellular rejection was lower in older patients [3, 5, 16] , and the present study also showed a similar result. Our immune suppression strategies have changed over time; however, the same strategies were used in the two groups. An age-related decrease in immune reactivity and T-cell function might be responsible for this effect [17] . In multivariable analysis, recipient age at the time of transplantation was not a risk factor for overall survival, but instead postoperative renal failure was the only significant risk factor.
There are limitations to the present study that must be recognized. First, this study was a nonrandomized, retrospective, observational study in a single institution. Second, the number of enrolled patients was relatively small for drawing definite conclusions. Third, the follow-up duration was different between the 2 groups because we began to perform heart transplantation in the elderly patients only recently.
CONCLUSION
The mortality and morbidity after heart transplantation did not increase significantly in the elderly patients (≥60 years), when compared with the younger patients (＜60 years). Heart transplantation might also be considered to be a treatment option for elderly heart failure patients, although careful patient selection criteria should be applied considering donor shortage in the current era.
